micro-community-banner
 
  • Saved

2yr
Adverse Event Reporting in Randomized Clinical Trials for Multiple Myelomad

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myelomad

Source : https://pubmed.ncbi.nlm.nih.gov/37948080/

These findings suggest that trial investigators and sponsors regularly use minimizing terms to describe toxic effects in MM trials, and use of this terminology may not reflect actual AE rates...

Trial investigators and sponsors regularly use minimizing terms to describe toxic effects in MM trials, and use of this terminology may not reflect actual AE rates in these studies.

  • Saved

2yr
Detection of Circulating Normal and Tumor Plasma Cells in Newly Diagnosed Patients of Multiple Myeloma and Their Associations With Clinical and Laboratory Parameters

Detection of Circulating Normal and Tumor Plasma Cells in Newly Diagnosed Patients of Multiple Myeloma and Their Associations With Clinical and Laboratory Parameters

Source : https://www.sciencedirect.com/science/article/abs/pii/S0147027223000788?via=ihub

Circulating plasma cells (CPCs) are frequently noted in variable frequencies in the entire spectrum of plasma cells neoplasms. With advent of high sen...

This study used multi-colour flow cytometry to evaluate the load of both CTPCs & CNPCs at the time of diagnosis and at six months’ time-point of therapy, and evaluated associations of both with clinical and laboratory parameters.

  • Saved

2yr
CAR T-Cell Therapy for Myeloma: Where Are We Now and What is Needed to Move CAR T-Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion From the American Society for Transplantation and Cellular Therapy

CAR T-Cell Therapy for Myeloma: Where Are We Now and What is Needed to Move CAR T-Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion From the American Society for Transplantation and Cellular Therapy

Source : https://www.sciencedirect.com/science/article/pii/S2666636723016445?via=ihub

Since 2021, two B-Cell Maturation Antigen (BCMA) directed chimeric antigen receptor T-cell (CAR T-cell) therapies, Idecabtagene vicleucel (ide-cel), a...

With the anticipation of the FDA possibly expanding approval of CAR T cells to earlier lines of myeloma therapy, the American Society for Transplantation and Cellular Therapy (ASTCT) convened a group of experts to provide a comprehensive review of the studies that led to approval of CAR T-cells in late line therapy of myeloma, discuss the...

  • Saved

2yr
2L management of RRMM

Multiple myeloma patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated progression on/within 60 days of completion of the last therapy may benefit from pomalidomide plus dexamethasone.

In the phase 2, single-arm MM-014 trial of DPd (pomalidomide + dexamethasone + daratumumab), patients with RRMM who received 1 or 2 prior treatment lines demonstrated an ORR of nearly 78.6% in the ITT population. The complete response (CR) was 26.8%; very-good partial response (VGPR), 25.9%; PR, 25.9%.

In other results, patients who relapsed after taking lenalidomide or who were refractory to lenalidomide had an ORR of 81.5% and 77.6%, respectively. As for secondary outcomes, median PFS was 23.7 months in the ITT population and median OS was 56.7 months. Overall, 8.9% of patients discontinued secondary to adverse events.

What is your treatment threshold to proceed to 2L therapy? How do you determine whether to dose adjust medications or change therapy altogether?

  • 2yr
    DPD with the above data is an option, and DKD - the carfilzomib-based regimen is also an option. It all depends on the patient's situation, what prior regimes the patient Show More
  • 2yr
    So with patients on maintenance once levels start going up just by adjusting dose usually buys 6 months on an average. Hence during that time need to start preparing and Show More

Show More Comments

  • Saved

2yr
Lipid Metabolic Vulnerabilities of Multiple Myeloma

Lipid Metabolic Vulnerabilities of Multiple Myeloma

Source : https://link.springer.com/article/10.1007/s10238-023-01174-2

Multiple myeloma (MM) is the second most common hematological malignancy worldwide, characterized by abnormal proliferation of malignant plasma cells within a tumor-permissive bone marrow microenvironment.

Understanding the oncogenic mechanisms of lipid metabolism and targeting lipid metabolism reprogramming to identify new MM dependencies have important scientific significance and holds potential for clinical translation.